Nanoligent — Series A (estimated) · €12M

Nanoligent, a spin-off of the Institut de Recerca Sant Pau and the Universitat Autònoma de Barcelona, closed a €12M round led by Inveready through its Inveready Biotech IV fund. Proceeds will complete regulatory preclinical development of NNL1524, a CXCR4-targeted nanodrug, and take it into a Phase Ia trial in solid tumours while scaling manufacturing.

LeadInveready RoundSeries A (estimated) Announced6 Oct 2025 CityBarcelona SectorHealthtech & Bio · Biotech / Oncology Source I S

Something wrong? Suggest a correction →